İmdat Eroğlu, Medical Oncology Fellow at Gazi University, shared a post on LinkedIn: about a recent article he and his colleagues co-authored, adding:
“In our recent bicentric study, we evaluated the efficacy and safety of neoadjuvant FLOT in Turkish and German patients.
Our findings revealed that clinical node status, rather than ethnicity, was the main determinant of major pathological response. Moreover, intensified neoadjuvant treatment (>4 cycles) did not improve pathological outcomes and was even associated with worse survival.
I am deeply grateful to our co-authors from University Hospital of Bonn, especially Dr. Christian Möhring and Prof. Maria A. Gonzalez-Carmona, for this valuable collaboration.
Special thanks to my professors at Gazi University for their contribution to this study and for their continuous support throughout my academic journey.”
Title: Efficacy and safety of neoadjuvant FLOT treatment for resectable gastric/gastroesophageal junction adenocarcinoma in Turkish and German patients; a real-world data
Authors: İmdat Eroğlu, Christian Möhring, Farsaneh Sadeghlar, Adrianna Mańczak, Ozan Yazıcı, Ahmet Özet, Nuriye Özdemir, Maria A Gonzalez-Carmona, Fatih Gürler
Read the Full Article on Springer Nature Link
More posts featuring İmdat Eroğlu.